secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001104659-25-100605
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; PDUFA April 10, 2026
--------------------------------------------------------------------------------

- FDA accepted resubmission of BLA for RP1 plus nivolumab in advanced melanoma patients who progressed on anti-PD-1 therapy.
- PDUFA target action date set for April 10, 2026 under Class II resubmission timeline.
- Resubmission addresses the complete response letter received in July 2025; includes additional data and analyses.
- Replimune CEO expressed commitment to working closely with FDA to expedite review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/0001104659-25-100605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer